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Abstract
Background: There is limited population-level research on end-of-life care in Australia that considers health care
use and costs across hospital and community sectors. The aim of this study was to quantify health care use and
costs in the last 6 months of life in a cohort of elderly Australian decedents and to examine the factors associated
with end-of-life resource use and costs.
Methods: A retrospective cohort study using routinely collected health data from Australian Government Department
of Veterans’ Affairs clients. The study included two cohorts of elderly Australians who died between 2005 and 2009;
one cohort with a recorded cancer diagnosis and a comparison cohort with no evidence of a cancer history. We
examined hospitalisations, emergency department (ED) visits, prescription drugs, clinician visits, pathology, and
procedures and associated costs in the last 6 months of life. We used negative binominal regression to explore factors
associated with health service use and costs.
Results: The cancer cohort had significantly higher rates of health service use and 27% higher total health care costs
than the comparison cohort; in both cohorts, costs were driven primarily by hospitalisations. Older age was associated
with lower costs and those who died in residential aged care incurred half the costs of those who died in hospital.
Conclusions: The results suggest differences in end-of-life care pathways dependent on patient factors, with younger,
community-dwelling patients and those with a history of cancer incurring significantly greater costs. There is a need to
examine whether the investment in end-of-life care meets patient and societal needs.
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Background
Elderly populations continue to grow, with estimates
that in Organisation for Economic Co-operation and De-
velopment (OECD) countries one in five people will be
65 years and older by 2030 [1] and, in developed coun-
tries, at least half of the population over 65 have more
than one chronic condition [2–5]. As populations be-
come sicker, they have increasing health care needs and
it is not surprising that per capita health care costs
increase with age [4]. However, the health care costs as-
sociated with ageing are low compared with costs in-
curred in the 6–12 months prior to death; some
estimates show that per capita health care costs are up
to four times higher in those at the end of life compared
with age-matched persons who are not at life’s end. For
example, Neuman et al. [4] found that in the USA, aver-
age Medicare per capita spending for beneficiaries age
96 ($US16,145) was more than double that for benefi-
ciaries age 70 ($US7,566) [4, 6].
There is a growing literature dedicated to understand-
ing patterns of health care use and costs at the end of
life, much of which has been conducted using routinely
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collected health care data [6–9]. The research highlights
the extensive array of health care services delivered at
the end of life and the high costs associated with care.
However, significant variability is reported in end-of-life
health care and costs which is dependent on a range of
patient and health system factors; one of the most con-
sistently important factors is age at death [8]. Several
studies show that the chance of receiving intensive or
life-sustaining treatments such as chemotherapy, emer-
gency department (ED) visits, and admission to intensive
care units and hospitals decreases with age [10–16]. As
such, it is not surprising that corresponding health care
costs decrease steadily with age, particularly in those
aged 85 years and older [4, 14, 15, 17, 18]. To date, the
majority of research on end-of-life care has been under-
taken in Europe or North America. Given the complex-
ities and jurisdiction-specific features of end-of-life care
for elderly patients, there is a need to conduct studies
that account for local health system characteristics such
as the relationship between primary and hospital-based
care, level of subsidisation of services and the availability
of hospice and palliative care services.
The aim of this study is to quantify health care use
and costs in the last 6 months of life in the Australian
setting and to examine the factors associated with end-
of-life care in an elderly decedent population. We com-
pare total health care use and costs in two elderly dece-
dent cohorts; a cohort with a history of cancer and a
cohort without a cancer history. We focused on compar-
ing cohorts with and without a previous cancer diagnosis
as cancer is the leading cause of death in Australia and
other similar countries and cancer patients represent a
significant proportion of patients receiving end-of-life
care [19, 20]. Additionally, patterns of end-of-life cancer
care are more extensively studied and understood than
other terminal diseases which provides an important
context within which to interpret our findings [21].
Methods
Setting
The Australian Government Department of Veterans’
Affairs (DVA) funds the health care of eligible veterans,
war widows, war widowers and their dependents. DVA
clients have access to the universal health care arrange-
ments provided to Australian permanent residents and
citizens plus additional DVA-approved services and
pharmaceutical items not subsidised for the general
population; the types of services subsidised depends on
the level of entitlement.
Study design and population
This study used data from the cancer and comparison
cohorts developed for the End of Life in Cancer Care
(EOL-CC) study, the details of which have been
published elsewhere [22]. Briefly, this is a retrospective
study of two decedent cohorts of Australian DVA clients
with full health care entitlements during the last
12 months of life to ensure near-complete capture of
health-related resource use and costs. Clients were eli-
gible for the study if they: resided in New South Wales
(Australia’s most populous state) in the 18 months prior
to death; were aged 65 years or older at death; died be-
tween June 30 2005 and December 31 2009; and re-
ceived at least one health service in the last 12 months
of life. The cancer cohort had a notifiable cancer diagno-
sis recorded in the NSW Central Cancer Registry be-
tween 1994 and 2009. The comparison cohort
comprised the remaining eligible clients with no evi-
dence of a cancer notification or any cancer related
health service use or cancer medicine; for more informa-
tion, see our study protocol [22].
Data sources and linkage
The data infrastructure comprises DVA data holdings
linked with NSW Ministry of Health data collections.
Data were linked by a third party under the custodian-
ship of the DVA, the NSW Ministry of Health and the
Cancer Institute NSW, using best practice, probabilistic,
privacy preserving protocols [23]. The linked datasets
capture information on DVA client characteristics, resi-
dence in an aged care facility, cancer notification history
and cause of death. However, we did not present infor-
mation on cause of death for the two cohorts because
information was only available to 2007. For those who
died in the period 2005–2007, the most common causes
of death in the cancer cohort were cancer (59%) and dis-
eases of the circulatory system (21%). For the compari-
son cohort, the most common causes of death were
diseases of the circulatory system (48%), lung disease
(7%) and dementia (9%); for more information see our
study protocol [23].
The linked datasets also include information about all
subsidised health services including hospital admissions,
emergency department (ED) presentations and dis-
pensed prescription medicines. Clinical consultations,
pathology services and procedures; procedures include
diagnostic services (e.g., ultrasound, CT, MRI), thera-
peutic services (e.g., radiotherapy) and surgery are also
captured; unit costs were available for all these services,
while costs for the hospital admissions and ED presenta-
tions were calculated per admission or presentation
using the methodology described in the NSW Costs of
Care Standards Report 2009/10. Full details of the cost-
ing methods are described elsewhere [22].
Statistical analyses
Outcomes were health service use and associated costs
in the last 6 months of life based on six constructed
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‘months’ consisting of 30 days each; all individuals are
observed for exactly 180 days to the date of death.
We calculated person-level mean (with 95% confi-
dence interval (CIs)) and median (with inter quartile
range (IQR)) service use and costs for the entire six-
month period, and by month until death.
We allocated unit costs to each item of resource use to
calculate mean (95% CI) and median (IQR) costs in 2009/
10 Australian dollars. Total costs were calculated as the
sum of costs of health services (excluding any services re-
ceived during a hospitalisation which are captured in hos-
pital costs), pharmacy, ED and hospital costs (excluding
the pharmacy component of hospital costs for private hos-
pital patients which is captured in the prescribing data-
base); more details are reported elsewhere [22, 24].
Factors associated with resource use and costs
We used negative binomial regression to determine fac-
tors associated with health service use and costs. The
cost data can be thought of as counts (of dollars and
cents). Cost data are non-negative and skewed so count
data models can be applied to these data, and in our
case this makes sense because it is consistent with the
method used for utilization [25]. Factors included: age,
sex, comorbidity burden, location of residence (remote-
ness, areas of socioeconomic disadvantage), year of
death, residence in an aged care facility and place of
death. These variables were selected based on common
factors found to predict patterns of health service use as
death approaches [22]. Comorbidity burden was esti-
mated in the periods prior to the last 6 months of life
using hospitalisation codes (Charlson index [26]) and
prescription dispensing history (RxRisk [27]); while the
Charlson is likely to under ascertain morbidity burden it
is more likely to capture people with severe morbidity,
e.g. those needing admission to hospital for the condi-
tion. Two indices were used to capture a more complete
morbidity history [22, 28].
Separate models were estimated for utilisation and costs
of each type of health service (i.e., clinician visits, path-
ology and procedures; prescription medicines dispensed;
ED visits and hospitalisations) and total health care costs.
The strength of associations was represented by adjusted
incident rate ratios with 95% CIs, and two-tailed p < 0.05
were used as a criterion for statistical significance.
We used SAS version 9.3 (SAS Institute) for data ma-
nipulation and performed statistical analyses using
STATA version 12 (StataCorp).
Results
Cohort characteristics [Table 1]
A total of 9862 decedents met the eligibility criteria for
the cancer cohort and 15,483 for the comparison cohort.
The cohorts were similar in relation to age, socioeconomic
status and geographical location of residence. Comorbidity
burden (based on hospitalisations) was higher in the can-
cer cohort; 17% of cancer decedents versus 10% of the
comparison cohort had a comorbidity score of three or
more. However, comorbidity burden was similar for both
cohorts when calculated based on prescription medicines
dispensed [Table 1].
Resource use and costs in the last 6 months of life
On average, decedents in the cancer cohort were dis-
pensed 41 medicines (vs. 38 medicines in the compari-
son cohort), received 90 clinician visits/procedures (vs.
66 in the comparison cohort) and had approximately
three hospital admissions (vs. two in the comparison co-
hort). The mean number of ED visits was similar in both
cohorts at about one visit/decedent in the last 6 months
of life [Additional file 1: Table S1].
The mean total cost associated with health care in the
last 6 months of life was higher in the cancer cohort
($28,091 per decedent) than the comparison cohort
($19,696 per decedent). Costs were driven primarily by
hospitalisations, accounting for about 80% of total costs
in both cohorts [Fig. 1].
Prescription medicines
The mean cost of medicines per person in the cancer
cohort was $1840 compared with $1234 for the com-
parison cohort. [Additional file 1: Table S1] The differ-
ence was driven by the costs of antineoplastic and
immunomodulation agents (mean of $469 per person in
the cancer cohort vs. $5 in the comparison cohort).
Clinician visits and procedures
Differences in utilisation can be attributed mainly to
higher numbers of medical specialist visits and pathology
services in the cancer cohort. The greatest difference in
health service costs related to diagnostic procedures at a
mean cost of $1041 per person in the cancer cohort
compared to $568 for the comparison cohort. The cost
of therapeutic procedures also differed substantially be-
tween cohorts, with mean costs of $877 and $464 per
person in the cancer and comparison cohorts respect-
ively [Additional file 1: Table S1].
Hospitalisations
The difference in hospitalisation costs was driven by the
higher number of admissions in the cancer cohort (mean
of three episodes per person costing $22,852 in total)
than the comparison cohort (two episodes per person
costing $15,893 in total). [Additional file 1: Table S1]
Only 15% of the cancer cohort and 3% of the comparison
cohort received a palliative service while in hospital; and
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4% of the cancer cohort and <1% of the comparison cohort
were admitted to a hospice [Additional file 1: Table S2].
Resource use and costs by month, during the last 6 months
of life [Figs. 2 and 3]
Rates of health service use and associated costs
increased over the last 6 months of life and peaked in
the last month of life. Total costs for both cohorts and
in each month to death are driven by the cost of hospi-
talisations [Fig. 1].
Factors associated with resource use and costs
Multivariable analyses demonstrate that cancer decedents
had significantly higher rates of prescription medicines
(adjusted IRR: 1.09; 95% CI: 1.08–1.11, p < 0.001); clin-
ician visits and procedures (adjusted IRR: 1.23; 95% CI:
1.20–1.25, p < 0.001); hospitalisations (adjusted IRR: 1.26;
95% CI: 1.23–1.30, p < 0.001) and ED visits (adjusted IRR:
1.05; 95% CI: 1.02–1.08, p < 0.001) than the comparison
cohort. Decedents aged over 90 at death had lower rates
of prescription medicines (adjusted IRR: 0.92; 95% CI:
0.90–0.93, p < 0.001); clinician visits and procedures (ad-
justed IRR: 0.81; 95% CI: 0.79–0.84, p < 0.001); hospitalisa-
tions (adjusted IRR: 0.76; 95% CI: 0.74–0.79, p < 0.001)
and ED visits (adjusted IRR: 0.91; 95% CI: 0.88–0.95,
p < 0.001) than younger decedents [Fig. 4].
Overall, cancer decedents incurred 27% higher health
care costs than non-cancer decedents, (adjusted IRR:
1.27; 95% CI: 1.24–1.30, p < 0.001) [Fig. 5]. The cancer
cohort had 42% higher costs for prescribed medicines
(adjusted IRR: 1.42; 95% CI: 1.39–1.46, p < 0.001), 32%
higher costs for clinician visits and procedures (adjusted
IRR: 1.32; 95% CI: 1.29–1.35, p < 0.001) and 28% higher
costs for hospitalisations (adjusted IRR: 1.28; 95% CI:





n (%) n (%)
Sex
Female 3116 (31.6) 7521 (48.9)
Male 6746 (68.4) 7962 (51.4)
Age in years: median (IQR) 86 (83–89) 87 (84–90)
Age at death
65–74 294 (3.0) 254 (1.7)
75–84 4075 (41.3) 5028 (32.5)
85–94 5215 (52.9) 9232 (59.6)
95–104 277 (2.8) 958 (6.2)
≥ 105 1 (0.0) 11 (0.1)
Year of death
2005 1204 (12.2) 1772 (11.4)
2006 2236 (22.7) 3199 (20.7)
2007 2351 (23.8) 3473 (22.4)
2008 2133 (21.6) 3619 (23.4)
2009 1938 (19.7) 3420 (22.1)
Age at cancer diagnosis:
Median (IQR)
83 (78–86) Not applicable
Years from diagnosis to death
years: Median (IQR)
1.6 (0.2–5.6) Not applicable
Location of residence (remoteness area)
Major cities 6147 (62.3) 9530 (61.6)
Inner Regional 2777 (28.2) 4400 (28.4)
Outer Regional 872 (8.8) 1410 (9.1)
Remote 39 (0.4) 81 (0.5)
Very Remote 5 (0.1) 2 (0.0)
Missing 22 (0.2) 60 (0.4)
Socioeconomic disadvantage index
(most disadvantaged) 1–2 1160 (11.8) 1862 (12.0)
3–4 2831 (28.7) 4470 (28.9)
5–6 2032 (20.6) 3085 (19.9)
7–8 1418 (14.4) 2248 (14.5)
(least disadvantaged) 9–10 2019 (20.5) 3183 (20.6)
Missing 402 (4.1) 635 (4.1)
Comorbidity burdena (based on hospitalisations)
0 3105 (31.5) 4451 (28.8)
1–2 1500 (15.2) 2068 (13.4)
≥ 3 1713 (17.4) 1578 (10.2)
Unable to calculate, no
hospitalisations
3544 (35.9) 7386 (47.7)
Table 1 Cohort characteristics (Continued)
Comorbidity burdenb (based on prescriptions)
0 461 (4.7) 846 (5.5)
1–2 1298 (13.2) 2130 (13.8)
3–5 3865 (39.2) 6104 (39.4)
≥ 6 4238 (43.0) 6403 (41.4)
Living in residential aged care at
any time during the last 6 months
of life
3659 (37.1) 8940 (57.7)
Place of death
Hospital 5740 (58.2) 6861 (44.3)
Residential aged care 2507 (25.4) 6435 (41.6)
Other 1615 (16.4) 2187 (14.1)
© Commonwealth of Australia 2017
aCharlson comorbidity index calculated using hospitalisations between 18 and
7 months before death
bRx-Risk comorbidity index calculated using dispensing history in the 6 month
period before the last 6 months of life (between month 12 and 7
before death)
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1.21–1.35, p < 0.001) than the comparison cohort. There
was no significant difference in costs associated with ED
visits (adjusted IRR: 1.05; 95% CI: 0.98–1.12, p = 0.166)
[Fig. 5]. A number of factors were associated with lower
health care costs: decedents aged over 90 at death had
20% lower health care costs than decedents aged 80–84
(adjusted IRR: 0.80; 95% CI: 0.77–0.82); decedents resid-
ing in residential aged facilities incurred 9% lower total
costs (adjusted IRR: 0.91; 95% CI: 0.88–0.95); and those
who died in residential aged care incurred less than half
the costs of those who died in hospital (adjusted IRR:
0.47; 95% CI: 0.45–0.49) [Fig. 5].
Fig. 1 Total health care costs in the last six months of life, by month and by health service type for the (a) cancer cohort and (b) comparison cohort
Fig. 2 Health service use and associated costs in the last 6 months of life, month. a Prescription medicines dispensed; and (b) Clinician visits,
pathology and procedures
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Fig. 3 Health service use and associated costs in the last 6 months of life, by month. a Hospital admissions and (b) Emergency Department visits
Fig. 4 Multivariable analysis examining the associations between cohort characteristics and costs in the last 6 months of life, by health service
type and total cost1
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Discussion
This study used routine health care data collections to
quantify and characterise factors associated with health
care use and costs at the end of life in elderly decedents.
Our results suggest wide variation in end-of-life care,
particularly when comparing decedents with and with-
out a cancer history. Decedents with a cancer history
had higher rates health services use and higher associ-
ated costs than non-cancer decedents. Age at death was
also a determinant of end-of-life care, with older dece-
dents in both cohorts using fewer health care services
than younger decedents. This is the first study of its kind
in Australia, yet the results align with studies conducted
internationally in terms of the impact of age on health
services use and distribution of health care costs, with
hospitals being the main driver of end-of-life costs [8].
Our results suggest systematic differences in the care
received by elderly populations, particularly those aged
85 years and over. The patterns of care received by this
group may suggest a different attitude towards active or
intensive treatment for this group compared with their
younger counterparts. Our finding that older decedents
were less likely to use hospital and ED services are simi-
lar to another study examining the entire NSW popula-
tion which reported that decedents aged 90 and older
were 60% less likely to have more than three hospital ep-
isodes and 85% less likely to spend time in the ICU than
those aged 60–79 years at death [29]. Our results show
that not only were elderly decedents (both cancer and
non-cancer) less likely to be admitted to hospital, but
also received fewer clinician visits and prescription med-
icines at the end of life. The reduced services in elderly
decedents may be compounded by the fact that this
group are more likely to live in residential aged care set-
tings; those who died in residential aged care incurred
half the health care costs of those who died in hospital.
While some literature suggests that lower rates of hos-
pital and ED use at the end of life may represent quality
care, [30] there is a need to further investigate whether
the reductions in end-of-life health service use in elderly
Fig. 5 Multivariable analysis examining the associations between cohort characteristics and health service use in the last 6 months of life
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decedents translate into appropriate treatment that is
consistent with patient preferences [31, 32]. We suggest
that the differences in care observed in this and other
studies does not necessarily represent inequities in treat-
ment. Rather, the very elderly may have their end-of-life
needs met with other sources of care [33, 34].
Services such as palliative hospital admissions and use
of hospice care are regarded as important for delivering
quality end-of-life care [7]. The proportion of people re-
ceiving palliative services in hospital in the last 6 months
of life was low (14.7% in the cancer cohort and 3.1% for
the comparison cohort); hospice admissions were also
low (4.1% and 0.5% respectively, for the same cohorts).-
While our findings are consistent with other studies
reporting the challenges of elderly patients accessing pal-
liative services in acute care settings, [35] a limitation of
our study is that rates of palliative care services delivered
may be underestimated due to coding practices in
Australia not being tied to hospital payment [36]. Never-
theless, the low rates of palliative services in this study
are important from a health care planning perspective
and warrant further examination. National data demon-
strate that less than half of all patients who die in hos-
pital receive any palliative care service [36].
Our findings have important policy implications within
the broader social and economic context of end-of-life
care. For instance, international studies and surveys of the
Australian population indicate that most people with a
terminal condition would prefer to die at home and prefer
a symptom management approach rather than intensive
treatment or heroic life-saving measures [37–39]. How-
ever, we found that hospital was the most common place
of death and also placed the greatest burden on the health
system in terms of costs. This indicates the need for more
widespread discussion between patients, providers, care-
givers, and health system managers about end-of-life plan-
ning (e.g., measures such as advanced care directives).
Indeed, patients’ awareness that their condition is terminal
and end-of-life discussions with clinicians have been
demonstrated to result in the delivery of care in-line with
patient preferences [31, 40]. There is also evidence that
suggests there is merit in increasing resources for
community-based palliative care services [41, 42]. While
our study is comprehensive in that it captures nearly all
health services from a health payer perspective, recent
studies considering costs more broadly found that
between one-fifth and one-third of overall end-of-life
care costs can be attributed to informal care givers
[43]. Costs of informal caregiving and patient prefer-
ences are not captured in routinely collected data
holdings but this information is needed to fully
understand how to maximise the value of end-of-life
care services at a population-level in a health care
environment with limited resources.
There are a number of strengths of our study, including
our comprehensive patient-level analysis using multiple
linked routine data collections. Our findings relating to
DVA clients may not be generalisable to the elderly
Australian cancer population. However, there is evidence
that DVA clients have similar rates of health service use
when compared with Australians of a similar age [44, 45]
and comparison with recent studies on end-of-life hospital
care in the general population suggest similar rates of
hospital admissions and ED visits [29, 46].
A study limitation is that we do not provide informa-
tion on patterns of end-of-life care in people under
65 years of age, a group that represents about 20% of all
deaths in Australia [47] and up to one third of cancer
deaths [20, 48]. Also there may have been changes in
practice in Australia since our study period ended in
2009; however, the data reflect the most recent available
at the time this research was undertaken. Another
potential limitation of our study is the retrospective
study design that does not necessarily reflect the chal-
lenges associated with predicting survival time in real
world clinical practice [49]. However, some research
comparing prospective and retrospective designs found
similar patterns of end-of-life health care [13, 50].
Conclusion
Decedents with a history of cancer used more services
and incurred higher costs in the last 6 months of life than
decedents without a cancer history. We also found evi-
dence of a shift in treatment patterns by age with dece-
dents aged 65–84 years receiving a greater number and
range of services (particularly hospital based services) than
those aged85 years and older. Future research is required
to understand which patterns of care are associated with
improved patient-reported care and to understand which
patterns of care represent the best value in terms of
appropriateness, quality and patient preferences.
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